Viread (VEER-ee-ad), the ONCE-DAILY antiretroviral drug

June 2004

You can now get Viread (VEER-ee-ad), the ONCE-DAILY antiretroviral drug...from Gilead Sciences.

Viread (tenofovir) is the first nucleoTIDE reverse transcriptase inhibitor. It's similar in structure to the nucleoSIDE reverse transcriptase inhibitors...but might be more active.

Viread also appears to have fewer drug interactions, cause fewer side effects, and might be less likely to develop resistance.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get quote

Which drug interactions really require your intervention
Gastroenterology new warnings about complications from severe diarrhea in patients taking Zelnorm (tegaserod)
Cardiology Does Vioxx (rofecoxib) cause more cardiovascular problems than other NSAIDs
Supplements vitamin D might help prevent falls in seniors
Supplements Hoodia is the latest craze for weight loss
Neurology & Pain Apomorphine will be more available for advanced Parkinson's
Diabetes Patients often ask which glucose meter is best
Diabetes Most diabetes patients should be taking a statin
Hematology & Oncology Zyprexa (olanzapine) to prevent nausea and vomiting in cancer patients
OTC Products Dulcolax, Excedrin and other OTCs often do not contain what you would expect
Women's Health home menopause tests
HIV & AIDS Viread (VEER-ee-ad), the ONCE-DAILY antiretroviral drug
Infectious Diseases Quinolones are losing their effectiveness for gonorrhea
Osteoporosis new LIQUID form of Fosamax

Viread (VEER-ee-ad), the ONCE-DAILY antiretroviral drug

Get concise advice on drug therapy, plus unlimited access to CE

Table of Contents